DiaMedica Therapeutics Financials - Benzinga

DiaMedica Therapeutics Inc

DMACNASDAQ

Trade with Public

Trade with Public

$6.52

Últ. Act.: Aug 20, 4:00 PM

Panorámica general Noticias Previsión de beneficios Eventos Precios objetivoFinanzasSentimiento Propiedad Comparar Opciones Informe de acciones

DiaMedica Therapeutics Financials

DiaMedica Therapeutics (DMAC) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
DiaMedica Therapeutics Q2 EPS $(0.19) Beats $(0.20) Estimate

DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.20) by 5 percent. This is a 5.56 percent decrease over losses of $(0.18) per share

Benzinga Newsdesk

Earnings Scheduled For May 6, 2026

Benzinga Insights

PRO
DiaMedica Therapeutics Q1 EPS $(0.19), Inline

DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.19) per share which met the analyst consensus estimate. This is a 5.56 percent decrease over losses of $(0.18) per share from the same period last

Benzinga Newsdesk

PRO
DiaMedica Therapeutics Q4 EPS $(0.17) Beats $(0.18) Estimate

Benzinga Newsdesk

Earnings Scheduled For March 30, 2026

Benzinga Insights

Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings

DiaMedica Therapeutics (NASDAQ: DMAC) will release Q4 earnings on March 30. Analysts expect a quarterly loss of 18 cents per share. Stock fell 0.9% on Friday.

Avi Kapoor

© 2026 Benzinga | All Rights Reserved